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 Abstract.  We assessed the effect of maternal human immunodeficiency virus (HIV) infection on birth outcomes and 
infant survival in rural Mozambique. Pregnant women attending the antenatal clinic were recruited. These women and 
their infants were followed-up for one year. Birth outcomes were assessed at delivery and infant HIV status was deter-
mined at 1 and 12 months of age. Women positive for HIV were more likely to have anemia at delivery than women 
negative for HIV (51.3% versus 35.4%;  P < 0.001). Infants born to HIV-positive mothers had a significantly higher post-
neonatal mortality rate than infants born to HIV-negative mothers (7.8% versus 1.9%;  P < 0.001). The rate of transmis-
sion of HIV by breastfeeding during the first year of life was 15.1% (95% confidence interval = CI 7.6–22.4). Assessment 
of the impact of HIV infection on birth outcomes in rural Africa is essential for tailoring public health measures to reduce 
mother-to-child transmission of HIV and excess infant mortality. 
 INTRODUCTION 
 Sub-Saharan Africa harbors more than two-thirds of the 
world’s 33.2 million persons infected with human immuno-
deficiency virus (HIV) and 80% of the world’s HIV-infected 
women. 1 In parts of southern Africa, more than 30% of preg-
nant women attending antenatal clinics are infected with HIV, 
thus making HIV infection one of the most common compli-
cations of pregnancy in sub-Saharan Africa. 1 
 With successful interventions, mother-to-child transmission 
(MTCT) of HIV has been reduced to less than 2% in devel-
oped countries. 2 However, in untreated populations, MTCT of 
HIV during pregnancy, delivery, and breastfeeding still occurs 
at an approximate overall rate of 25–40%, 3,4 and accounts for 
almost 420,000 new HIV infections in children and 270,000–
320,000 pediatric deaths annually. 1,5 Until 2004, single-dose 
intrapartum and neonatal nevirapine (sd-NVP) was the rec-
ommended regimen by the World Health Organization to 
prevent MTCT of HIV among women without access to 
antiretroviral therapy. Preventive MTCT programs with an 
sd-NVP have been shown to decrease perinatal HIV transmis-
sion to 8% in controlled clinical trial settings. 6 However, there 
is great concern about the rapid development of resistance. In 
addition, in predominantly breastfeeding populations of sub-
Saharan Africa, most MTCT of HIV still occurs during the 
postnatal period. 4 Currently, MTCT prevention programs in 
sub-Saharan African countries include zidovudine and lami-
vudine during the final weeks of pregnancy and sd-NVP at 
delivery. In addition, the newborn receives sd-NVP at birth 
and zidovudine for seven days. 7 Nevertheless, effectiveness of 
these strategies relies on the great challenge of availability of 
the drugs and compliance with them, given that these preven-
tive regimens are prolonged and unsupervised. 
 Several studies from the Africa have reported that HIV-
infected pregnant women are at increased risk of adverse 
pregnancy outcomes such as spontaneous abortion, still-
births, and preterm labor. 8–10 However, this analysis is com-
plicated by many factors associated with HIV infection and 
poor pregnancy outcomes such as malnutrition, anemia, and 
other frequent infections such as syphilis or malaria. 11 These 
factors may contribute to the observation that the association 
between HIV infection and adverse pregnancy outcomes is 
stronger in women from developing countries. 12,13 
 Maternal HIV infection has also been associated with an 
increased risk of infant death. 5,14,15 It is well documented that 
up to 35% of HIV-infected infants may die before the first 
year of age, 1 but HIV-negative children born to HIV-infected 
mothers are also at high risk of mortality. 15 
 There have been few studies characterizing the impact 
of HIV infection during pregnancy on the mother and her 
infant 5,16,17 and even fewer from rural African settings. 14,18 The 
main aim of this study was to assess the impact of HIV infec-
tion on birth outcomes and infant survival in a rural area of 
southern Mozambique. Furthermore, the study also evaluated 
the effect of unsupervised sd-NVP administration for preven-
tion of MTCT of HIV on HIV RNA viral load at delivery and 
the prevalence of NVP resistance mutations. 
 METHODS 
 Study population.  The study was conducted from August 
2003 through October 2006 at the Manhiça District Hospital in 
Manhiça District, Maputo Province, in southern Mozambique. 
The Centro de Investigaçao em Saúde de Manhiça has been 
conducting continuous demographic surveillance in the 
Manhiça District since 1996 that covers a population of 82,000 
persons. 19 
 The prevalence of HIV infection in pregnant women attend-
ing the antenatal clinic in 2004 was approximately 21%. 20 
During the study, highly active anti-retroviral treatment was 
not available, and the national policy on prevention of MTCT 
of HIV relied upon the self-administration of sd-NVP to the 
mother at the onset of labor and to the newborn within the 
first 72 hours of life. Because NVP uptake by the mother was 
unsupervised, maternal adherence to the sd-NVP regimen 
was ascertained by interview prior to delivery. Breastfeeding 
was common with more than 90% of children in the area 
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breastfeeding during the first six months of age (Menendez C, 
unpublished data). 
 Study design.  This study was integrated into a randomized, 
double-blind, placebo-controlled trial (RCT) of two-dose 
intermittent preventive treatment (IPTp) with sulfadoxine-
pyrimethamine (SP) for malaria prevention in pregnancy 
(trial registration no. NCT00209781). All study participants 
had been given a long-lasting insecticide treated bed net 
through the antenatal clinic. Details of the RCT design are 
given elsewhere. 20 Pregnant women participating in the RCT 
were invited to participate in the study of HIV, birth out-
comes, and MTCT 21 if they accepted HIV testing at the vol-
untary counseling and testing (VCT) center. The current study 
started after the RCT had been initiated. Thus, baseline CD4 
cell counts and HIV RNA viral load data are only available 
for the HIV-positive women enrolled during the second half 
of the trial, although HIV RNA viral load data is available for 
all HIV-positive women at delivery and one-month postpar-
tum. The study was reviewed and approved by the National 
Mozambican Ethics Committee and the Hospital Clinic of 
Barcelona Ethics Review Committee. 20,21 
 Follow up and sample collection.  After written informed 
consent was obtained, a capillary blood sample was collected 
as part of the routine antenatal care to assess anemia and 
for syphilis screening. The HIV-1 viral status and the CD4 
cell counts of the mother were determined at time of enroll-
ment after voluntary counseling. Women with indeterminate 
results were invited to return one month later for testing. The 
HIV RNA viral load and CD4 cell counts were determined at 
enrollment, at delivery, and at one-month postpartum. Recent 
HIV infections in the mother (less than six months prior to 
enrollment) were determined on a subset of women (80 of 
93) from whom a sufficient blood sample was available at the 
time of the enrollment visit. The mid-upper arm circumference 
(MUAC) was also measured to assess the nutritional status. 
All women were encouraged to deliver at Manhiça District 
Hospital. 
 At the time of delivery, venous blood was collected from 
the mother and the umbilical cord for hematologic and para-
sitologic determinations, and a placental biopsy sample was 
collected for malaria examination. A placental blood sample 
was collected for placental HIV-1 RNA assays from the 
women enrolled during the second half of the trial. Comparison 
of peripheral malaria at delivery and placental malaria 
between HIV-positive and HIV-negative women is only 
shown on the group of women who received placebo because 
the IPTp with SP was found to be effective in reducing the 
risk of malaria infection in the mother in the main RCT. 20 
Newborns were weighed on a digital scale, accurate to the 
nearest gram. 
 The mother was examined 4–6 weeks postpartum for hema-
tologic, parasitologic, and viral determinations. Infants were 
visited at 4–6 weeks and 12 months of age. At each visit, infants 
were examined and weighed, and a capillary blood sample was 
collected for hematologic, parasitologic, and viral determina-
tions. An HIV-DNA polymerase chain reaction (PCR) was 
carried out at these two visits. To confirm HIV status, children 
with positive HIV-DNA PCR results at any of these visits 
were invited to return for a second test one month later. The 
HIV-DNA PCR was performed at 12 months of age to con-
firm HIV infection at one month, if not confirmed earlier, and 
to identify transmission caused by breastfeeding. According to 
national guidelines, at 18 months of age, children were invited 
to return for serologic HIV testing at the VCT program. 
 Laboratory methods.  Maternal HIV status was assessed 
using the Determine HIV-1/2 Rapid Test (Abbott Laboratories, 
Abbott Park, IL) and positive results were confirmed by the 
Uni-Gold Rapid Test (Trinity Biotech Co., Wicklow, Ireland). 
The HIV status of the infants was assessed using the Amplicor 
HIV-1 DNA-PCR kit (Roche Diagnostics, Branchburg, NJ). 
Recent maternal HIV infections were determined using 
the Calypte HIV-1 BED Incidence Enzyme Immunoassay 
(Calypte Biomedical Corporation, Lake Oswego, OR). 
 Maternal HIV RNA viral load was determined from cryo-
preserved peripheral and placental plasma using the Amplicor 
HIV-1 Monitor assay version 1.5 (Roche Diagnostics). The 
assay has a sensitivity of 400 copies/mL. For the purpose of 
analyses, plasma HIV-1 RNA concentrations below the limit 
of detection were assigned the value of 200 copies/mL. The 
CD4 cell counts were determined by flow cytometry after 
staining of whole blood with fluorochrome-labeled antibodies 
to CD3, CD8, and CD4 cells and acquisition using Truecount 
tubes (Becton Dickinson, Franklin Lakes, NJ). Mutations 
known to confer resistance to nevirapine were assessed after 
reverse transcription–PCR and sequencing of codons 26–245 
of the HIV-1 reverse transcriptase gene from a subsample of 41 
women one month after delivery with primers and conditions 
as described previously. 22 The Stanford University HIV Drug 
Resistance database (aIgProgram) ( http://hivdb.stanford.edu ) 
was used to determine resistance-associated mutations. 
 Determination of maternal and infant anemia was per-
formed by assessment of packed cell volume (PCV) in a 
microhematocrit centrifuge and reading in a Hawksley hemat-
ocrite reader (Hawksley-Gelman, Lancing, United Kingdom). 
Syphilis screening was performed with the rapid plasma reagin 
test, (Syphacard; Burroughs-Wellcome, Research Triangle 
Park, NC). 
 Statistical methods and definitions.  Malaria infection was 
defined as any density of asexual  Plasmodium falciparum par-
asites in a blood smear. Malnutrition was defined as MUAC ≤ 
22 cm. Anemia in pregnant women was defined as a PCV 
less than 33% and severe anemia as a PCV less than 21%. 
Placental malaria was defined as the presence of parasites 
and/or pigment in a histologic examination. Fetal anemia was 
defined as a PCV less than 37% in cord blood and/or less than 
42% in the newborn peripheral blood. Perinatal HIV infec-
tion was defined as a positive HIV DNA-PCR result at 4–6 
weeks of age. Infection with HIV during breastfeeding was 
defined as a negative HIV DNA-PCR result at 4–6 weeks of 
age and a positive HIV DNA-PCR result at 12 months of age. 
A recent HIV infection in the mother was considered as an 
infection occurring within the previous six months before the 
enrollment visit. Anemia in infants was defined as a PCV less 
than 33%, and low birth weight as a birth weight lower than 
2,500 grams. Early neonatal mortality refers to a death of a 
live-born baby within the first seven days of life, and late neo-
natal mortality covers the time between 7 and 29 days of life. 
Post neonatal death includes the remaining 11 months of the 
first year of life. 23 
 Microsoft FoxPro version 5.0 (Microsoft Corp., Redmond, 
WA) was used for data entry, validation, and cleaning of data, 
and statistical analysis was performed with STATA release 9 
(StataCorp, College Station, TX). Proportions for categorical 
variables were assessed using the chi-square test or Fisher’s 
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 T able 1
Characteristics of 207 HIV-positive and 660 HIV-negative pregnant women enrolled in the study* 
 * Values are median (interquartile range) or no. positive/no. tested (%). HIV = human immunodeficiency virus; RPR = rapid plasmin reagent; PCV = packed cell volume. Because several variables 
had missing data, the total number of persons analyzed does not always add to 207 (HIV positive) and 660 (HIV negative). 
 †  Proportions were compared using the chi-square test unless otherwise stated. 
 ‡  By Wilcoxon rank sum test. 
 §  Malnutrition is defined as a mid-upper arm circumference £ 22 cm. 
 ¶  Malaria infection was assessed on the subset of women who did not receive sulfadoxine-pyrimethamine (placebo group). 
 #  Placental malaria was defined as parasites and/or pigment observed in a histologic examination and/or in an impression smear. 
Characteristic HIV+ HIV−  P †
Age, years 23 (20–29) 22 (18–28) 0.005‡
Gravidity
Primigravid 53/207 (25.6) 184/660 (27.9) 0.814
Secundigravid 46/207 (22.2) 142/660 (21.5)
Multigravid 108/207 (52.2) 334/660 (50.6)
Literate 73/206 (35.4) 273/659 (41.4) 0.126
Malnutrition at enrollment§ 6/164 (3.7) 7/524 (1.3) 0.057
RPR 31/207 (15) 72/660 (10.9) 0.115
PCV < 33% at delivery 102/199 (51.3) 224/633 (35.4) < 0.001
Peripheral malaria at delivery¶ 17/86 (19.8) 43/324 (13.3) 0.130
Placental malaria# 40/75 (53.3) 143/274 (52.2) 0.861
exact test where appropriate. The Wilcoxon rank sum test 
was used to compare independent continuous variables with 
non-normal distribution. McNemar’s chi-square test and the 
Wilcoxon signed rank were used for analysis of paired data 
for categorical and continuous variables, respectively. The 
Spearman correlation was used to assess correlations between 
non-normally distributed variables. Probability of MTCT dur-
ing the first year of life was calculated as 1 − (negative propor-
tion at 1 month × negative proportion at 12 month). 
 RESULTS 
 A total of 1,030 women were enrolled in the RCT, 20 of which 
870 women accepted HIV testing. Of these women, 207 were 
HIV positive and 660 were HIV negative. 
 Maternal outcomes in HIV-positive and HIV-negative 
pregnant women.  Comparison of demographic and analytical 
parameters between HIV-positive and HIV-negative women 
are shown in  Table 1 . The average gestational age at enroll-
ment was 24 weeks. The mean ± SD time between HIV testing 
and delivery was 3.7 ± 1 month. The HIV-positive women were 
significantly more likely to have anemia at delivery (51.3% 
[102 of 199] in HIV-positive women versus 35.4% [224 of 633] 
in HIV-negative women) ( P < 0.001) ( Table 1 ). There was no 
evidence of a higher proportion of HIV-positive women with 
peripheral malaria parasitemia at delivery (19.8%, 17 of 86) 
than HIV-negative women (13.3%, 43 of 324) ( P = 0.130). 
There was also a trend for a higher proportion of HIV-positive 
women with a positive syphilis test result (15% [31 of 207] ver-
sus 10.9% [72 of 660] in HIV-negative women) ( P = 0.115). 
The HIV-positive women had a higher prevalence of malnu-
trition compared with HIV-negative women (3.7% [6 of 164] 
versus 1.3% [7 of 524]) ( P = 0.057). 
 Birth outcomes in HIV-positive and HIV-negative pregnant 
women.  Excluding 7 second live-born twins and 2 live-born 
triplets, there were 839 live-born singleton babies, 199 of 
whom were born to HIV-positive women and 640 of whom 
were born to HIV-negative women. Median birth weight 
tended to be lower in infants born to HIV-positive moth-
ers versus HIV-negative mothers (3,000 g versus 3,040 g; 
 P = 0.064). Although not statistically significantly different 
( P = 0.156), the proportion of low birth weight babies born to 
HIV-positive women was also higher as compared with HIV-
negative women (13.8% versus 10.1%) ( Table 2 ). 
 There was a 1.5-fold higher prevalence of anemia at 1 month 
of age among infants born to HIV-positive women (20%, 32 
of 160) compared with infants born to HIV-negative women 
(13.8%, 71 of 514) ( P = 0.058) ( Table 2 ). Malaria parasitemia 
at one month of age was similar in both groups of infants 
( P = 0.640). There was no evidence of an association between 
spontaneous abortion, premature delivery, stillbirth or neona-
tal death and HIV status of the mother ( Table 2 ). 
 Overall infant mortality was 2.3-fold higher in babies born 
to HIV-positive women than those born to HIV-negative 
women ( P = 0.002) ( Table 2 ). When separated into neonatal 
death and post-neonatal death, infants born of HIV-positive 
mothers had a higher post neonatal mortality rate (7.8%, 15 
of 193) than those born to HIV-negative mothers (1.9%, 12 of 
623) ( P < 0.001). Early and late neonatal death were similar 
in infants born to HIV-positive women and to HIV-negative 
women. The lost to follow-up was low and equally distributed 
between infants born to HIV-positive women and those born 
to HIV-negative women ( P = 0.86, by log rank test for equality 
of lost to follow-up). Potential bias could be a slight underesti-
mation of the post neonatal mortality. 
 Viral and immunologic parameters of HIV infection in 
pregnant women.  The proportion of women refusing the test 
and the proportion of women positive for HIV changed over 
the study duration. During the first half of recruitment (from 
August 2003 through May 2004), the prevalence of HIV was 
18.4% (78 of 423) (95% confidence interval [CI] = 14.7–22.0), 
with 17.9% (92 of 515) of women refusing VCT. However, dur-
ing the second half of recruitment (from May 2004 through 
April 2005), the prevalence of HIV increased to 29% (130 
of 447) (95% CI = 24.9–33.4), and the percentage of women 
refusing VCT decreased to 13.2% (68 of 515). The prevalence 
of HIV was significantly different by age group (18.2% [50 of 
274] in women less than 20 years of age, 27.4% [113 of 413] in 
women 20–30 years of age, and 24.4% [44 of 280] in women 
more than 30 years of age;  P = 0.026, by Fisher’s exact test). 
 Characterization of the proportion of women with recent 
HIV infection (< 6 months) was performed on a subset of 
women at the time of the enrollment visit (as described in 
the Materials and Methods). Fifteen (18.8%) of 80 women 
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analyzed (95% CI = 10–27.5) had an HIV infection contracted 
within the previous six months. 
 The median peripheral HIV RNA viral load increased 
between enrollment to one-month post-delivery, although the 
difference did not reach statistical significance ( P = 0.215, by 
signed rank test for paired observations) ( Table 3 ). The propor-
tion of HIV-positive women with HIV RNA viral load greater 
than 10,000 copies/mL was similar at the time of enrollment 
and at delivery (59.1% and 60.3%, respectively). However 
this value increased to 69.5% one month after delivery 
( P = 0.014, by McNemar’s chi square test for paired obser-
vations). Placental HIV RNA viral load was measured in a 
subset of 57 women and showed a median of 8,728 copies/
mL (interquartile range [IQR] = 2,098–46,467), which was 
lower than that in peripheral blood (17,515 copies/mL, IQR = 
4,800–69,492), although not significantly different ( P = 0.240) 
( Table 2 ). 
 Median CD4 cell counts increased significantly in the inter-
val between enrollment and one-month post-delivery ( Table 3 ). 
Furthermore, at time of enrollment, 28% of the women had 
CD4 cell counts less than 350/µL, whereas one-month after 
delivery this percentage decreased to 7% ( P < 0.001, by 
McNemar’s chi-square test for paired observations). The 
increase in CD4 cell counts was accompanied by a slightly 
larger increase in CD8 cell counts, leading to a small but signif-
icant decrease in the CD4:CD8 ratio ( P = 0.003) ( Table 3 ). 
 Impact of sd-NVP administration on MTCT of HIV and 
development of resistance mutations.  Although, 84% of the 
women reported taking their NVP tablet at the onset of labor 
and all infants received a NVP dose during the first 72 hours 
of life, no evidence was found of differences between maternal 
HIV RNA viral load at enrollment and at delivery ( Table 3 ). 
Sequencing a region in the HIV RT gene showed that 22% 
(9 of 41) of sequences amplified harbored at least one high-
level resistance mutation, with two sequences harboring two 
resistance mutations. K103N was the most prevalent mutation, 
as described by others. 24 All viruses studied were subtype C. 25 
 Mother-to-child transmission of HIV.  Results assessing 
MTCT of HIV infants at one month of age were available for 
77% of live births where HIV DNA was detected in 12.4% of 
infants as described previously. 21 From those infants who were 
negative for HIV DNA at one month of age and for whom 
HIV testing was available at 12 months of age, an additional 
15.1% (14 of 93) (95% CI = 7.6–22.4) were HIV DNA posi-
tive. Overall risk of mother-to-child transmission of HIV dur-
ing the first year of life was calculated to be 25.6%. 
 Infant mortality was evaluated in babies born to HIV-
infected mothers according to the HIV status of the infant at 
one month of age. During the first year of life, 26.3% (5 of 19) 
of HIV-positive infants died compared with 3.7% (5 of 134) 
HIV-negative infants ( P = 0.003) ( Table 4 ). For those 46 with 
no HIV test available at one month of age, there were five 
deaths (10.9%) over the first year of life. 
 DISCUSSION 
 This study assessed the impact of maternal HIV infection on 
birth outcomes and infant mortality in a rural area of southern 
Mozambique. It also described viral and immunologic param-
eters of HIV infection in pregnant women and their evolution 
in the postpartum. The findings of this study show that anemia 
at delivery was more common among HIV-positive women 
than in HIV-negative women. No statistically significant differ-
ences in adverse pregnancy outcomes, such as low birth weight, 
 T able 2 
Adverse pregnancy and neonatal outcomes by HIV status of the mother* 
 * Values are median (interquartile range) or no. positive/no. tested (%). HIV = human immunodeficiency virus; IQR = interquartile range. 
 †  Proportions were compared using the chi-square test unless otherwise stated. 
 ‡  Calculated from live births (excludes spontaneous abortions and stillbirths). 
 §  By Wilcoxon rank sum test. 
 ¶  Fetal anemia was defined as a packed cell volume < 37% in cord blood £ 42% in newborn peripheral blood 
 #  By Fisher’s exact test. 
Outcome HIV+ mothers (n = 199) HIV- mothers (n = 640)  P †
Birth weight, grams‡ 3,000 (2,600–3,300) 3,040 (2,780–3,340) 0.064§
Low birth weight infants 27/196 (13.8) 64/631 (10.1) 0.156
Fetal anemia¶ 14/175 (8) 45/554 (8.1) 0.960
Infant anemia at one month 32/160 (20) 71/514 (13.8) 0.058
Infant parasitemia at one month 2/168 (1.2) 4/524 (0.8) 0.640#
Spontaneous abortion 4/207 (1.9) 5/660 (0.8) 0.229#
Pre-term 10/167 (6) 19/522 (3.6) 0.190
Stillbirth 4/203 (2) 15/655 (2.3) 1#
Infant mortality‡ 21/199 (10.6) 29/640 (4.5) 0.002
Early neonatal death 4/199 (2) 13/640 (2) 1#
Late neonatal death 2/195 (1) 4/627 (0.6) 0.630#
Post-neonatal death 15/193 (7.8) 12/623 (1.9) < 0.001
 T able 3
Viral and immunologic parameters of HIV-positive women* 
Parameter No. Median IQR  P †
Maternal HIV RNA viral load (copies/mL)
Enrollment‡ 93 16,409 3,548–52,967 –
Delivery 194 17,515 4,800–69,492 0.540
One-month 
post-delivery 156 24,589 6,017–81,250 0.215
CD4 cell counts (cells/μL)
Enrollment 95 492 329–634 –
One-month 
post-delivery 84 635 460–827 < 0.001
CD8 counts (cells/μL)
Enrollment 95 726 547–935 –
One-month 
post-delivery 84 1,063 787–1,257 < 0.001
Ratio of CD4:CD8 cell counts
Enrollment 95 0.64 0.49–0.86 –
One-month 
post-delivery 84 0.595 0.45–0.775 0.001
 * HIV = human immunodeficiency virus; IQR = interquartile range. 
 † By Wilcoxon signed rank test. 
 ‡ Women were enrolled at the time of voluntary counseling and testing. 
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spontaneous abortions, preterm delivery, and stillbirth, were 
observed between HIV-positive and HIV-negative women. 
However, infants born to HIV-positive women had more than 
twice a higher risk of death than infants born to HIV-negative 
women. Several studies from sub-Saharan Africa suggest that 
HIV-infected mothers may be at increased risk of adverse 
pregnancy outcomes, especially for those women with ane-
mia 26 or CD4 cell counts less than 200 cells/µL. 9,27 
 In this study the observed rates of adverse pregnancy out-
comes in the HIV-positive and HIV-negative women were 
similar to those found in other studies. 9,12 No statistically sig-
nificant differences were found in the comparison between 
HIV-positive and HIV-negative women for low birth weight, 
spontaneous abortion, premature delivery, or stillbirth rates. 
However, there was a trend towards increased rates among 
HIV-positive women for most of these outcomes. The lack of 
statistical significance of these trends is likely caused by the 
small sample size. 
 The prevalence of anemia at delivery was significantly 
higher among HIV-infected women (51.3%) than among 
HIV-negative women (35.4%), which indicated that HIV 
infection was likely to be an etiologic factor of maternal ane-
mia. Both HIV and malaria infection have been shown to be 
independent risk factors for maternal anemia. 26,28,29 This find-
ing is consistent with reported prevalence of anemia in preg-
nant African women ranging from 50% to 80%, irrespective 
of HIV status. 30,31 
 Maternal HIV infection was significantly associated with an 
excess infant mortality regardless of the HIV infection status 
of the infant. These findings are consistent with those of pre-
vious studies that have described maternal HIV infection as a 
risk factor for infant mortality. 5,15,18,32 Several known risk fac-
tors for infant mortality associated with HIV infection include 
low birth weight, maternal anemia, maternal CD4 cell counts 
less than 200 cells/µL, or high maternal HIV RNA viral load 
in HIV-infected women. 5,33,34 A recent community-based study 
in Rakai, Uganda 18 showed two-year mortality rates of 540, 
166, and 128 per thousand child-years among HIV-infected 
children, HIV-negative children of HIV-positive mothers, and 
HIV-negative children of HIV-negative women, respectively. 
Interestingly, maternal HIV infection was strongly associated 
with post-neonatal death but not with early and late neona-
tal death. Early and late neonatal death have been shown 
to be related to low birth weight and congenital malforma-
tions regardless of HIV status of the mother. 26,35 Undeniably, 
infant mortality is complex and multifactorial, and risk factors 
change with age of the infant. This complexity must be taken 
into account when optimizing targets for implementation of 
public health interventions to reduce infant mortality. 
 The study began recruitment when VCT was implemented 
at Manhiça District Hospital. During the second year of the 
study, and probably because of a change of perception towards 
HIV testing, the percentage of women refusing counseling 
and testing decreased considerably, and the proportion of 
women positive for HIV increased significantly from 18.2% 
to 29%. Prevalence of HIV is increasing in the region, 1,25 and 
improved compliance for HIV testing may also lead to test 
acceptance by patients with higher risk of being HIV positive. 
Although HIV incidence data is not available in this popula-
tion, almost 20% of the women in whom recent HIV infec-
tions where analyzed had contracted the infection within the 
previous six months. This finding suggests rapid spread of 
the HIV epidemic in this area over recent years. 25 Consistent 
with previous reports, HIV-infected women were significantly 
older than HIV-negative women, which may be explained by 
the HIV epidemic history in southern Africa. Furthermore, 
malnutrition, syphilis, and malaria, although not significantly 
associated in this study with HIV infection, appeared to be 
more common among HIV-infected women. This finding is 
consistent with compiled evidence reporting the synergistic 
effect of HIV infection with other infectious diseases and defi-
ciency status. 36,37 
 As reported in a previous study, the rate of MTCT of HIV 
by 4–6 weeks of age found in this population was 12.4%. 21 
This finding is similar to the 14.8% rate observed in KwaZulu 
Natal, South Africa by eight weeks of age 9 where the routine 
administration of NVP was also unsupervised. 6 Furthermore, 
in this study the rate of MTCT in the first year of life (exclud-
ing perinatal transmission) was 15.1%, which highlights the 
urgent need to address the issue of breastfeeding transmission, 
including evaluation of the use of antiretroviral prophylaxis in 
the infant or the mother during breastfeeding. 4,38,39 
 The NVP resistance rate of 22% is low compared with pub-
lished studies showing 69% mutation rates, 24,40 particularly 
given the fact that it has been suggested that subtype C may be 
associated with detection of increased NVP-resistance muta-
tions after sd-NVP when compared with A and D subtypes. 41 
The fact that we did not observe a significant decrease in mater-
nal HIV RNA viral load between recruitment and delivery 
but rather a tendency towards an increase, as well as the 
surprisingly low resistance rate to NVP, suggests inadequate 
compliance with sd-NVP in this cohort despite high self-
reported adherence. Some increase in HIV RNA viral load 
might have been explained by HIV disease progression. 
Recent reports in various sub-Saharan African countries 
have suggested that there may be an important gap between 
the efficacy of sd-NVP in the prevention of MTCT of HIV 
in a clinical trial setting and its effectiveness when imple-
mented under real life conditions. 42–44 Difficulties are likely to 
be caused by improper self-administration of NVP and poor 
compliance. 
 This study provides further evidence to support pub-
lic health efforts in improving deployment of antiretrovi-
ral therapy during pregnancy and infancy in breastfeeding 
populations. Maternal HIV infection jeopardizes infant sur-
vival during infancy. Thus, effective public health measures to 
reduce MTCT of HIV during the first year of life is urgently 
needed to avoid excess mortality in the child. In conclu-
sion, the epidemiology of HIV infection is not homogeneous 
throughout sub-Saharan Africa, and assessment of the effect 
of HIV infection on pregnancy outcomes and infant survival 
 T able 4
HIV status and mortality in infants born to HIV-positive women* 
Status n/N % 95% CI  P 
Sex of HIV-infected infants perinatally†
Male 9/79 11.4 4.2–18.6 0.690
Female 10/74 13.5 5.5–21.5
Infant mortality
HIV+ 5/19 26.3 4.5–48 0.003‡
HIV- 5/134 3.7 0.4–7
 *  HIV = human immunodeficiency virus; CI = confidence interval. 
 †  Perinatal period covers the time until 4–6 weeks of age. 
 ‡  By Fisher’s exact test. 
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in rural African populations is necessary to guide targeted 
public health actions. 
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